Complete Filing Data
Turn Therapeutics Inc. reported Stockholders Equity of $4.69 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Turn Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Research And Development Expense | $265.6K | $246.0K |
| Operating Income Loss | -$5.9M | -$1.8M |
| Operating Expenses | $5.9M | $1.8M |
| Nonoperating Income Expense | $2.7M | $28.7K |
| Net Income Loss | -$3.2M | -$1.8M |
| General And Administrative Expense | $5.6M | $1.6M |
| Other Nonoperating Income Expense | $176.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Research And Development Expense | $158.7K | $153.3K |
| Operating Income Loss | -$1.9M | -$673.0K |
| Operating Expenses | $1.9M | $673.0K |
| Nonoperating Income Expense | $9.4K | $6.6K |
| Net Income Loss | -$1.9M | -$666.4K |
| General And Administrative Expense | $1.8M | $519.7K |
| Other Nonoperating Income Expense | $4.3K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | $4.7M | -$177.4K | $85.8K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $5.1M | $872.6K | $1.2M |
| Retained Earnings Accumulated Deficit | -$22.4M | -$19.2M | |
| Prepaid Expense And Other Assets Current | $120.3K | $225.3K | |
| Operating Lease Right Of Use Asset | $78.6K | $120.5K | |
| Operating Lease Liability Noncurrent | $34.1K | $80.4K | |
| Operating Lease Liability Current | $46.3K | $40.7K | |
| Liabilities Current | $6.0M | $707.9K | |
| Liabilities And Stockholders Equity | $12.2M | $2.0M | |
| Liabilities | $7.5M | $2.2M | |
| Intangible Assets Net Excluding Goodwill | $922.2K | $821.9K | |
| Contract With Customer Liability Noncurrent | $1.4M | $1.4M | |
| Common Stock Value | $2.9K | $2.7K | |
| Cash Equivalents At Carrying Value | $5.1M | $872.6K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations | $4.2M | -$308.4K | |
| Assets Current | $5.2M | $1.1M | |
| Assets | $12.2M | $2.0M | |
| Additional Paid In Capital Common Stock | $28.1M | $19.0M | |
| Accounts Payable And Other Accrued Liabilities Current | $2.9M | $667.3K | |
| Stockholders Equity Note Subscriptions Receivable | $1.1M | ||
| Stock Issued During Period Value Issuance Of Common Stock Under Regulation D Net Of Issuance Costs | $2.9M | ||
| Stock Issued During Period Value Issuance Of Common Stock Under Regulation A Net Of Issuance Costs | $280.5K | ||
| Noncash Operating Lease Expense | $1.2K | $8.7K | |
| Common Stock Issued In Exchange For Services | $250.0K | ||
| Write Off Of Deferred Debt Issuance Cost | $496.9K | ||
| Stock Issued During Period Value Issuance Of Common Stock For Draw Down Notice | $2.6M | ||
| Stock Issued During Period Value Common Stock For Deferred Offering Cost | $850.0K | ||
| Stock Issued During Period Shares Issuance Of Common Stock For Draw Down Notice | 1.2M | ||
| Settlement Of Forward Contract Liability For Sale Of Shares To GEM Pursuant To Initial Draw Down Notice | 380.4K | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $133.6K | ||
| Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 | $5.6M | ||
| Gain From Change In Fair Value Of Forward Contract Liability | -$380.4K | ||
| Derivative Liabilities Current | $3.0M | ||
| Deferred Costs | $6.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Stockholders Equity | $504.0K | -$414.3K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $3.1M | $788.8K |
| Retained Earnings Accumulated Deficit | -$22.7M | |
| Prepaid Expense And Other Assets Current | $188.6K | |
| Operating Lease Right Of Use Asset | $89.4K | |
| Operating Lease Liability Noncurrent | $46.3K | |
| Operating Lease Liability Current | $44.8K | |
| Liabilities Current | $2.3M | |
| Liabilities And Stockholders Equity | $4.3M | |
| Liabilities | $3.8M | |
| Intangible Assets Net Excluding Goodwill | $904.9K | |
| Contract With Customer Liability Noncurrent | $1.4M | |
| Common Stock Value | $2.8K | |
| Cash Equivalents At Carrying Value | $3.1M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations | ||
| Assets Current | $3.3M | |
| Assets | $4.3M | |
| Additional Paid In Capital Common Stock | $23.2M | |
| Accounts Payable And Other Accrued Liabilities Current | $2.3M | |
| Stockholders Equity Note Subscriptions Receivable | $52.7K | |
| Stock Issued During Period Value Issuance Of Common Stock Under Regulation D Net Of Issuance Costs | ||
| Stock Issued During Period Value Issuance Of Common Stock Under Regulation A Net Of Issuance Costs | ||
| Noncash Operating Lease Expense | ||
| Common Stock Issued In Exchange For Services | ||
| Write Off Of Deferred Debt Issuance Cost | ||
| Stock Issued During Period Value Issuance Of Common Stock For Draw Down Notice | ||
| Stock Issued During Period Value Common Stock For Deferred Offering Cost | ||
| Stock Issued During Period Shares Issuance Of Common Stock For Draw Down Notice | ||
| Settlement Of Forward Contract Liability For Sale Of Shares To GEM Pursuant To Initial Draw Down Notice | ||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | ||
| Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 | ||
| Gain From Change In Fair Value Of Forward Contract Liability | ||
| Derivative Liabilities Current | ||
| Deferred Costs |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Proceeds From Issuance Of Common Stock | $6.9M | $1.2M |
| Share Based Compensation | $419.2K | $352.8K |
| Payments To Acquire Intangible Assets | $153.0K | $99.5K |
| Net Cash Provided By Used In Operating Activities | -$2.6M | -$1.4M |
| Net Cash Provided By Used In Investing Activities | -$153.0K | -$99.5K |
| Net Cash Provided By Used In Financing Activities | $6.9M | $1.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$105.0K | $204.5K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | $2.3M | $202.6K |
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $419.2K | $352.8K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 27.7M | 26.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 27.7M | 26.6M |
| Earnings Per Share Diluted | $-0.12 | $-0.07 |
| Earnings Per Share Basic | $-0.12 | $-0.07 |
| Common Stock Shares Issued | 29.4M | 26.8M |
| Common Stock Shares Authorized | 500.0M | 40.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 28.0M | 26.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 28.0M | 26.6M |
| Earnings Per Share Diluted | $-0.07 | $-0.03 |
| Earnings Per Share Basic | $-0.07 | $-0.03 |
| Common Stock Shares Issued | 28.0M | |
| Common Stock Shares Authorized | 500.0M | |
| Common Stock Par Or Stated Value Per Share | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Investment Income Interest | $29.6K | $28.7K |
| Stock Issued During Period Value New Issues | $777.8K | $1.2M |
| Security Deposit | $8.6K | $8.6K |
| Stock Issued During Period Value Other | $238.00 | |
| Stock Issued During Period Value Issued For Services | $250.0K | |
| Depreciation And Amortization | $52.7K | $47.5K |
| Stock Issued1 | $850.0K | |
| Gain Loss On Derivative Instruments Net Pretax | $2.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Investment Income Interest | $5.1K | $6.6K |
| Stock Issued During Period Value New Issues | ||
| Security Deposit | $8.6K | |
| Stock Issued During Period Value Other | ||
| Stock Issued During Period Value Issued For Services | ||
| Depreciation And Amortization | ||
| Stock Issued1 | ||
| Gain Loss On Derivative Instruments Net Pretax |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.